Detalhe da pesquisa
1.
Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Diabetologia
; 2024 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38584180
2.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
N Engl J Med
; 384(11): 989-1002, 2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33567185
3.
Obesity pharmacotherapy in older adults: a narrative review of evidence.
Int J Obes (Lond)
; 2024 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38710803
4.
Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.
Curr Atheroscler Rep
; 26(1): 1-10, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38148417
5.
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
; 145(21): 1581-1591, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510542
6.
New insights into the treatment of obesity.
Diabetes Obes Metab
; 25(8): 2058-2072, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055715
7.
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Diabetes Obes Metab
; 25(12): 3621-3631, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667658
8.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Eur Heart J
; 43(31): 2958-2967, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427295
9.
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Lancet
; 398(10296): 262-276, 2021 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216571
10.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 380(4): 347-357, 2019 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30415602
11.
Long-term effects of dapagliflozin plus saxagliptin versus glimepiride on a background of metformin in patients with type 2 diabetes: Results of a 104-week extension to a 52-week randomized, phase 3 study and liver fat MRI substudy.
Diabetes Obes Metab
; 24(1): 61-71, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514692
12.
The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab
; 24(8): 1509-1521, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441435
13.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes Obes Metab
; 24(8): 1553-1564, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35441470
14.
The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review.
Diabetologia
; 64(2): 288-303, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33164108
15.
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Diabetologia
; 64(6): 1226-1234, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33611623
16.
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
Circulation
; 141(15): 1227-1234, 2020 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31983236
17.
Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.
Circulation
; 142(8): 734-747, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795086
18.
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.
Int J Obes (Lond)
; 45(5): 923-933, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462358
19.
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
Diabetes Obes Metab
; 23(4): 1020-1029, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368855
20.
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
Diabetes Obes Metab
; 23(1): 29-38, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32844557